ADI
65
5
WFC
57
7
LOW
55
5
MSI
66
8
BLK
72
2
BWA
55
2
BMY
43
2
IVZ
69
3
DD
56
6
SCHW
61
5
KR
69
-2
FOX
62
11
ORLY
58
-4
RHI
19
5
SYF
79
7
MPC
52
2
MU
72
4
PCG
86
3
NDAQ
60
-2
FTI
55
2
ADI
65
5
WFC
57
7
LOW
55
5
MSI
66
8
BLK
72
2
BWA
55
2
BMY
43
2
IVZ
69
3
DD
56
6
SCHW
61
5
KR
69
-2
FOX
62
11
ORLY
58
-4
RHI
19
5
SYF
79
7
MPC
52
2
MU
72
4
PCG
86
3
NDAQ
60
-2
FTI
55
2
Financhill
Back

Aligos Therapeutics 10K Form

Sell
23

ALGS
Aligos Therapeutics

Last Price:
$7.49
Seasonality Move:
-14.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALGS News And Ratings

See the #1 stock for the next 7 days that we like better than ALGS

ALGS Financial Statistics

Sales & Book Value

Annual Sales: $3.9M
Cash Flow: $-15.6M
Price / Cash Flow: 0
Annual Sales: $14.65
Price / Book: 0.51

Profitability

EPS (TTM): -19.79000
Net Income (TTM): $-74.2M
Gross Margin: --
Return on Equity: -120.95%
Return on Assets: -67.11%

Aligos Therapeutics Earnings Forecast

Key Aligos Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,781.22% of Revenue.
  • The Net Earning history of ALGS is -3,326.01% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 4 years.

Aligos Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALGS
Website: aligos.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.31
Quick Ratio: 6.07

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALGS Technical Analysis vs Fundamental Analysis

Sell
23
Aligos Therapeutics (ALGS) is a Sell

Is Aligos Therapeutics a Buy or a Sell?